Science Translational Medicine
07 June 2017 Vol 9, Issue 393
Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake
By Frank Liang, Gustaf Lindgren, Kerrie J. Sandgren, Elizabeth A. Thompson, Joseph R. Francica, Anja Seubert, Ennio De Gregorio, Susan Barnett, Derek T. O’Hagan, Nancy J. Sullivan, Richard A. Koup, Robert A. Seder, Karin Loré
Science Translational Medicine07 Jun 2017 Restricted Access
Vaccine responses are initiated in vaccine-draining lymph nodes and depend on the efficiency by which adjuvants influence antigen uptake.
Moving beyond mice for vaccine studies
Vaccine enhancement by adjuvants has been known for decades, but the mechanistic differences in how specific adjuvants influence the immune response are just beginning to be elucidated. Liang et al. sought a model that closely mimics humans, so they intramuscularly immunized nonhuman primates with a prototypical HIV antigen in combination with various adjuvants. They then inspected the muscles and lymph nodes to characterize antigen-presenting cells and resulting adaptive immune responses. Their findings should provide valuable information on adjuvant selection for vaccine development in humans.